The phrase "a reduction in cv" is correct and usable in written English.
It can be used in contexts discussing a decrease in a variable, such as "coefficient of variation" (cv) in statistics or finance.
Example: "The recent analysis showed a significant reduction in cv, indicating improved consistency in the data set."
Alternatives: "a decrease in cv" or "a decline in cv".
43 Analysis of recent data shows that treatment of type 2 diabetes mellitus with a TZD increases signs of CHF, but not the risk of CV and overall death, and type 2 diabetics with preexisting HF benefit from a reduction in CV end-points.
The conventional FBF algorithm produced less of a reduction in CV (even after excluding unrealistic data).
The statin class has extensive data supporting a reduction in CV [cardiovascular] risk burden and Lipitor's ability to reduce cardiovascular morbidity and mortality has been demonstrated in 12 CV outcomes trials.
Orloff emphasized that the FDA guidance does not require demonstration of a reduction in CV risk.
A reduction in CV mortality has been demonstrated, however, in the past decade.
In many trials in which a reduction in CV events was documented, antihypertensive therapy was diuretic-based (3– 8).
There was also a reduction in overall CV mortality (HF and other CV mortality HR: 0.91; 95% CI 0.80 to 1.03, p=0.128), however, this result did not achieve statistical significance.
5 The United Kingdom Prospective Diabetes Study (UKPDS) 1 10 years after it ended and the Steno study 6 found a 50% reduction in CV outcomes at 8 years and a 30% reduction in mortality at 13 years associated with treating glucose, blood pressure, and lipids to goal levels.
However, before being recommended as a target for antihypertensive treatment in daily clinical practice, further prospective outcome studies should be conducted to support that a treatment-induced reduction in BPV is accompanied by a corresponding reduction in CV risk over and above that already achieved by reducing mean BP levels.
We did not attempt to obtain cardiovascular (CV) outcomes for these patients, though recent data suggest that statin adherence is associated with a significant reduction in CV events and revascularization [ 17] and is therefore a valid surrogate outcome marker.
Although this systematic overview has inherent and important limitations, the data support a potential reduction in CV events with saxagliptin.
